CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $75.19 Consensus PT from Analysts

CRISPR Therapeutics AG (NASDAQ:CRSP) has been assigned an average rating of “Hold” from the nineteen ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $75.19.

Several analysts have commented on CRSP shares. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, August 8th. Truist Financial cut their price target on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, August 12th. Needham & Company LLC decreased their price objective on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Stifel Nicolaus cut their target price on shares of CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. Finally, Barclays decreased their price target on shares of CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 6th.

Insider Activity

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the sale, the general counsel now directly owns 62,597 shares in the company, valued at $2,896,989.16. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the transaction, the chief executive officer now directly owns 226,540 shares in the company, valued at approximately $10,484,271.20. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of large investors have recently modified their holdings of the company. Capital International Investors lifted its stake in CRISPR Therapeutics by 27.8% during the first quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock worth $534,175,000 after purchasing an additional 1,702,624 shares during the last quarter. SR One Capital Management LP acquired a new position in shares of CRISPR Therapeutics in the 1st quarter valued at $71,496,000. Farallon Capital Management LLC acquired a new position in shares of CRISPR Therapeutics in the 2nd quarter valued at $28,625,000. Avoro Capital Advisors LLC purchased a new position in shares of CRISPR Therapeutics in the 1st quarter valued at $28,599,000. Finally, Marshall Wace LLP acquired a new stake in CRISPR Therapeutics during the 2nd quarter worth $10,078,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Price Performance

NASDAQ:CRSP opened at $49.00 on Monday. The company’s fifty day moving average price is $47.14 and its 200-day moving average price is $53.59. CRISPR Therapeutics has a 1-year low of $37.55 and a 1-year high of $91.10. The firm has a market capitalization of $4.16 billion, a P/E ratio of -18.01 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, August 5th. The company reported ($1.49) EPS for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The company had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $12.31 million. During the same quarter last year, the business posted ($0.98) earnings per share. The firm’s revenue for the quarter was down 99.3% compared to the same quarter last year. Equities analysts anticipate that CRISPR Therapeutics will post -5.6 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.